Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial. (ELPIS II)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04925024 |
Recruitment Status :
Recruiting
First Posted : June 14, 2021
Last Update Posted : April 9, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypoplastic Left Heart Syndrome | Biological: Lomecel-B medicinal signaling cells | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 38 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS) : A Phase IIb Clinical Trial. |
Actual Study Start Date : | June 25, 2021 |
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | August 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Lomecel B Group
Participants randomized to receive Lomecel-B injections during their Stage II palliation.
|
Biological: Lomecel-B medicinal signaling cells
A single administration of Lomecel-B will be performed via 6-10 intramyocardial injections into the right ventricle during the participant's standard of care stage II palliation. Dosing is based on body weight. Each patient will be given 2.5 x 10^5 cells per kg of body weight. The entire dose of the cells will be roughly 600 microliters. |
No Intervention: No Study Intervention Control Group
Participants randomized to receive no study intervention during their Stage II palliation.
|
- Change in right ventricular ejection fraction (RVEF) [ Time Frame: Baseline, 12 Months ]Efficacy will be reported as change in right ventricular ejection fraction (RVEF) assessed as a percentage and will be measured via cardiac magnetic resonance (CMR) imaging.
- Change in right ventricular ejection fraction (RVEF) [ Time Frame: Baseline, 6 Months ]Efficacy will be reported as change in right ventricular ejection fraction (RVEF) assessed as a percentage and will be measured via cardiac magnetic resonance (CMR) imaging.
- Change in right ventricular mass index at diastole [ Time Frame: Baseline, 12 Months ]Efficacy will be reported as change in right ventricular mass index at diastole assessed as g/m^2 and will be measured via serial cardiac magnetic resonance (CMR) imaging.
- Change in right ventricular end-diastolic volume index (RVEDVI) [ Time Frame: Baseline, 12 Months ]Efficacy will be reported as change in right ventricular end diastolic volume index (RVEDVI) assessed as ml/m^2 and will be measured via serial cardiac magnetic resonance (CMR) imaging.
- Change in right ventricular end-systolic volume index (RVESVI) [ Time Frame: Baseline, 12 Months ]Efficacy will be reported as change in right ventricular end systolic volume index (RVESVI) assessed as ml/m^2 and will be measured via serial cardiac magnetic resonance (CMR) imaging.
- Change in right ventricular global longitudinal strain and strain rate [ Time Frame: Baseline, 12 Months ]Efficacy will be reported as change in right ventricular global longitudinal strain and strain rate assessed as % and s^-1 respectively and will be measured via serial cardiac magnetic resonance (CMR) imaging.
- Change in right ventricular global circumferential strain and strain rate [ Time Frame: Baseline, 12 Months ]Efficacy will be reported as the change in right ventricular global circumferential strain and strain rate as % and s^-1 respectively, and will be measured via serial cardiac magnetic resonance (CMR) imaging.
- Change in right atrial volume index [ Time Frame: Baseline, 12 Months ]Efficacy will be reported as the change in right atrial volume index as ml/m^2 and will be measured via serial cardiac magnetic resonance (CMR) imaging.
- Change in right ventricular work index [ Time Frame: Baseline, 12 Months ]Efficacy will be reported as the change in right ventricular work index as (mmHg x mL x beats) / min and will be measured via serial cardiac magnetic resonance (CMR) imaging.
- Change in tricuspid regurgitation severity [ Time Frame: Baseline, 12 Months ]Efficacy will be reported as change in the categorical qualitative assessment of tricuspid valve regurgitation (trivial, mild, moderate, severe) and will be measured via transthoracic echocardiography.
- Change in RV compliance/diastolic function [ Time Frame: Baseline, 12 Months ]Efficacy will be reported as change in diastolic function as measured by the tricuspid E/E' ratio, evaluating the tricuspid inflow E and A velocities and ratio, and tricuspid annular DTI E'A' velocities. Function reported as normal diastolic function (no abnormalities in these measures), mildly impaired diastolic function (1 abnormal measure), moderately impaired diastolic function (2 abnormal measures), and severely impaired diastolic function (3 abnormal measures). These measures will be measured via transthoracic echocardiography.
- Change in weight [ Time Frame: Baseline, 12 Months ]Efficacy measured as change in participant's weight in kg and will be measured serially to assess change in somatic growth.
- Change in length (height) [ Time Frame: Baseline, 12 Months ]Efficacy measured as change in participant's length (height) in cm and will be measured serially to assess change in somatic growth.
- Change in head circumference [ Time Frame: Baseline, 12 Months ]Efficacy measured as change in participant's head circumference in cm and will be measured serially to assess change in somatic growth.
- Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) [ Time Frame: Baseline, 12 Months ]Efficacy measured as change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) in pg/ml and will be measured serially by blood draw.
- Change in modified Ross Heart Failure Classification score [ Time Frame: Baseline, 12 Months ]The Ross Heart Failure Classification provides a global assessment of heart failure severity in infants. Efficacy measured as change in classification and will be measured serially via physician's assessment using the modified Ross Heart Failure Classification; classifications defined as Class 1 (no limitations of physical activity); Class 2 (may experience symptoms during moderate exercise but not during rest); Class 3 (symptoms with minimal exertion that interfere with normal daily activity); Class 4 (unable to carry out physical activity/has symptoms at rest that worsen with exertion).
- Change in PedsQL™ Infant Scales [ Time Frame: Baseline, 12 Months ]The PedsQL™ Infant Scales is a generic health related quality of life instrument specifically for healthy and ill infants ages 1-24 months. Efficacy measured as change in PedsQL total improvement score and will be measured serially by parental proxy-report. Higher scores are indicative of better quality of life.
- Freedom from unplanned catheter intervention needed to address the pulmonary arteries or aorta. [ Time Frame: Baseline, 12 Months ]Efficacy measured as the number and percentage of participants who do not undergo unplanned catheter interventions to address pulmonary arteries or the aorta.
- Change in biomarkers/cytokines [ Time Frame: Baseline, 12 Months ]Efficacy measured as change in biomarkers/cytokines in pg/ml and/or ng/ml and will be measured serially by blood draw.
- Participants experiencing treatment emergent serious adverse events (TE-SAEs) [ Time Frame: 30 days post Stage II palliation ]Safety will be reported as the number of participants experiencing treatment emergent serious adverse events (TE-SAEs) assessed by treating physician within the 30 days following study procedure. These include: greater than 30 seconds of sustained/symptomatic ventricular tachycardia requiring intervention; cardiogenic shock; unplanned cardiovascular operation for bleeding due to right ventricular intramyocardial injection site bleeding in the first five days after stage II palliation; worsening of cardiac function; local infection or systemic infection; need for new permanent pacemaker; death.
- Participants experiencing major adverse cardiac events (MACE) [ Time Frame: Baseline, 12 Months ]Safety will be reported as the number of participants with adjudicated events including cardiovascular morbidity; need for transplantation; re-hospitalizations; cardiovascular mortality; all-cause mortality.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 12 Months (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion:
All participants must have HLHS (includes all types) requiring Stage II palliation (Glenn or Hemi-Fontan operation).
Exclusion:
- Requirement for ongoing mechanical circulatory support immediately prior to Stage II palliation within 5 days
- Need for concomitant surgery for aortic coarctation or tricuspid valve repair or Endocardial fibroelastosis (EFE) resection or left ventricle recruitment procedures
- Undergoing the Stage I (Norwood) procedure that does not have HLHS
-
Serum positivity for: human immunodeficiency virus (HIV); hepatitis B virus surface antigen (HBV BsAg); and/or viremic hepatitis C virus (HCV). This criterion can be ascertained by one of three ways:
- Documented history of mother's testing conducted during pregnancy
- Documented history of participants testing.
- If above documentation is not available blood will be obtained from participant at Screening/Baseline.
- Parent/guardian that is unwilling or unable to comply with necessary follow-up
- Unsuitability for the study based on the Investigator's clinical opinion
- Known hypersensitivity to dimethyl sulfoxide (DMSO)
- Presence of a pacemaker, or anticipated placement of a pacemaker, at the time of the Stage II palliation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04925024
Contact: Stephanie Brazis, MPH | 312-227-0201 | sbrazis@luriechildrens.org | |
Contact: Kiran Mansoor, MBBS | 713-500-9643 | Kiran.Mansoor@uth.tmc.edu |
United States, California | |
Children's Hospital of Los Angeles | Recruiting |
Los Angeles, California, United States, 90027 | |
Contact: Carly Weaver 323-361-8631 cweaver@chla.usc.edu | |
Contact: Brandi Scott 323-361-7086 bscott@chla.usc.edu | |
Principal Investigator: John Cleveland, MD | |
United States, Georgia | |
Children's Healthcare of Atlanta | Recruiting |
Atlanta, Georgia, United States, 30322 | |
Contact: Emily Klingman, MSN, RN 404-785-7153 emily.klingman@choa.org | |
Contact: Rachna Prasad 404-785-7294 Rachna.Prasad@choa.org | |
Principal Investigator: William Mahle, MD | |
United States, Illinois | |
Advocate Children's Hospital | Terminated |
Chicago, Illinois, United States, 60453 | |
Ann & Robert H. Lurie Children's Hospital of Chicago | Recruiting |
Chicago, Illinois, United States, 60611 | |
Contact: Carmen Diaz-Leos 312-227-5395 cdiazleos@luriechildrens.org | |
Contact: Stephanie Brazis 312-227-0201 sbrazis@luriechildrens.org | |
Principal Investigator: Kiona Allen, MD | |
United States, Massachusetts | |
Boston Children's Hospital | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact: Michael Bamgbose 617-919-4457 Michael.Bamgbose@cardio.chboston.org | |
Contact: Jonah Leighton 617-919-4457 Jonah.Leighton@childrens.harvard.edu | |
Principal Investigator: Sitaram Emani, MD | |
United States, Nebraska | |
Children's Nebraska | Recruiting |
Omaha, Nebraska, United States, 68114 | |
Contact: Morgan Loeffelbein 402-889-2822 mloeffelbein@unmc.edu | |
Principal Investigator: Ram K Subramanyan, MD, PhD | |
United States, Ohio | |
Cincinnati Children's Hospital Medical Center | Terminated |
Cincinnati, Ohio, United States, 45229 | |
United States, Texas | |
UTHealth-McGovern Medical School | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Rebecca Sam 713-500-5746 Rebecca.M.Sam@uth.tmc.edu | |
Contact: Rosie Munoz 713-500-7510 Rosie.Munoz@uth.tmc.edu | |
Principal Investigator: Damien LaPar, MD | |
United States, Utah | |
Primary Children's Hospital/University of Utah | Recruiting |
Salt Lake City, Utah, United States, 84113 | |
Contact: Linda Lambert, ARPN 801-587-7523 Linda.lambert@hsc.utah.edu | |
Principal Investigator: Adil Husain, MD | |
Principal Investigator: Edem Binka, MD |
Principal Investigator: | Stu Berger, MD | Ann & Robert H Lurie Children's Hospital of Chicago |
Publications:
Responsible Party: | Longeveron Inc. |
ClinicalTrials.gov Identifier: | NCT04925024 |
Other Study ID Numbers: |
2021-4531 7UG3HL148318-02 ( U.S. NIH Grant/Contract ) 1U24HL148316-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | June 14, 2021 Key Record Dates |
Last Update Posted: | April 9, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Hypoplastic Left Heart Syndrome Pediatrics Heart Defects Congenital Cardiovascular Diseases Stem Cells |
Hypoplastic Left Heart Syndrome Syndrome Disease Pathologic Processes Heart Defects, Congenital |
Cardiovascular Abnormalities Cardiovascular Diseases Heart Diseases Congenital Abnormalities |